**
The rising popularity of GLP-1 weight-loss medications such as Ozempic and Wegovy has prompted several US states to reconsider their Medicaid coverage policies, leading to significant reductions in access for low-income residents. While some lawmakers argue that cutting coverage could provide immediate fiscal relief, experts warn that such measures may result in more substantial long-term healthcare expenses linked to obesity-related conditions.
A Surge in Demand and Costs
The obesity crisis in the United States is stark; as of August 2023, the adult obesity rate reached a staggering 40%, according to the Centers for Disease Control and Prevention. The demand for GLP-1 drugs has seen a dramatic rise, with a 6% increase in adults reporting usage from November 2025, as highlighted by KFF. These medications have been linked to a decrease in the national obesity rate, which fell to 37% in 2025, according to a Gallup report. However, the financial implications of this trend cannot be ignored.
In 2023 alone, spending on GLP-1 drugs soared to $71.7 billion—an astronomical 500% increase from the $13.7 billion spent in 2018, as reported in the medical journal Jama. This surge has put immense pressure on state Medicaid programmes, which provide essential health insurance to low-income individuals.
States Restricting Access
As the costs associated with GLP-1 drugs escalate, several states have begun to curtail their Medicaid coverage for these weight-loss treatments. Notably, California, New Hampshire, Pennsylvania, and South Carolina have discontinued coverage for weight-loss indications, while Michigan has limited access to those classified as morbidly obese—defined as having a body mass index (BMI) above 40. In New York City, the health insurer for municipal employees has also ceased coverage for these medications, and Boston is contemplating similar limitations due to rising insurance premiums largely attributed to GLP-1 drug costs.
The trend reflects a broader budgeting crisis exacerbated by political decisions, including the One Big Beautiful Bill Act introduced by former President Donald Trump, which is projected to slash state Medicaid funding by $665 billion over the next decade.
Health Implications and Legislative Responses
Healthcare professionals are voicing concerns over the potential health ramifications of these cuts. Dr Matthew Klebanoff, a professor of internal medicine at the Perelman School of Medicine, emphasised the importance of access to these therapies. “It’s just very challenging right now for payers to be able to afford covering these medications for everyone who could benefit,” he stated.
In Pennsylvania, for instance, Medicaid spending on GLP-1 drugs reached $1.3 billion in 2025—double that of the previous year. State officials, including Secretary of Human Services Val Arkoosh, have indicated that the goal is to ensure these medications are utilised appropriately while considering cost-effectiveness. As a result, coverage is now restricted to individuals with diabetes or those meeting specific health criteria.
The situation has sparked legislative responses, with Pennsylvania state representative Arvind Venkat proposing a subscription-based model for GLP-1 drugs. This model would allow the state to negotiate value-based arrangements with drug manufacturers, reminiscent of a 2019 agreement in Louisiana for hepatitis C medications, which provided unlimited access for a fixed fee. However, experts believe that drug manufacturers may lack the incentive to engage in such arrangements due to the already high demand for their products.
The Road Ahead for Medicaid Recipients
As states grapple with the financial implications of covering GLP-1 drugs, many Medicaid recipients are left to navigate a challenging landscape. Individuals like Alexa Canciello, who had success with the GLP-1 drug Zepbound before coverage was cut, now face substantial out-of-pocket expenses. Her father, Rich, highlighted the challenges faced by those who genuinely require these medications, stating, “There are a lot of people out there that could probably lose weight without GLP-1 drugs… but there is a segment of the population that cannot lose weight.”
In the interim, experts suggest that individuals may seek alternative pathways, such as undergoing sleep studies to qualify for GLP-1 prescriptions based on related health issues. Venkat argues that the state’s focus should extend beyond immediate budgetary savings, emphasising the importance of sustaining public health.
Why it Matters
The tightening of Medicaid coverage for GLP-1 weight-loss drugs raises critical questions about the balance between fiscal responsibility and public health. While state governments may find short-term financial relief by restricting access, the potential long-term costs associated with untreated obesity could far outweigh these savings. As the landscape of healthcare funding evolves, it is imperative that policymakers consider the broader implications of their decisions on the health and well-being of vulnerable populations. The future of effective obesity treatment hinges not only on affordability but also on the commitment to maintaining access for those who need it most.